Select Bibliography

Filter by any of these (after searching):

Sarkaria, J.

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 3 items

NCCTG phase I trial of Everolimus (RAD001) and Temozolomide (TMZ) in combination with radiation therapy (RT) in newly diagnosed glioblastoma multiforme (GBM) patients (N057K).

Sarkaria, J. N. , Galanis, E. , Peller, P. J. , Brown, P. D. , Wu, W. ... - EORTC-NCI-AACR - Mol Cancer Ther - 2009

Abstract - Primary - Primary - Neuro-Onc - NCCTG-N057K

NCCTG phase I trial of temsirolimus (CCI-779) and temozolomide (TMZ) in combination with radiation therapy (RT) in newly diagnosed glioblastoma multiforme (GBM) patients

Sarkaria, J. N. , Galanis, E. , Wu, W. , Giannini, C. , Jaeckle, K. A. ... - ASCO - J Clin Oncol - 2009

Abstract - Primary - Primary - Neuro-Onc - NCCTG-N027D

Feasibility/tolerability results from a phase I/II study of temsirolimus (CCI-779) and sorafenib in recurrent glioblastoma: North Central Cancer Treatment Group (NCCTG) N0572

Schiff, D. , Sarkaria, J. , Decker, P. , Buckner, J. , Galanis, E. ... - SNO - Neuro-oncology - 2009

Abstract - Primary - Preliminary - Neuro-Onc - NCCTG-N0572